The hunt for antifibrotic and profibrotic botanicals

Qihe Xu, Yibin Feng, Pierre Duez, Bruce Hendry, Peter J. Hylands

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Fibrosis is a leading cause of mortality. This pressing challenge must be addressed through robust strategies, by developing efficacious anti-fibrotics and by preventing exposure to fibrogenic stimuli. This perspective paper briefly reviews anti-fibrotic and pro-fibrotic botanicals, especially those with inflammation-independent activities, leading to our proposal that future research should focus on efficacy, safety, innovation and good practice. An efficacy-based strategy is put forward for discovering anti-fibrotics; innovative modeling is emphasized for studying both anti-fibrotic therapeutics and pro-fibrotic hazards. At present, with funding insufficient to establish and maintain good practice, botanical research is generally perceived a risky area, but considerable morbidity and mortality risks also exist if we disregard anti- and pro-fibrotic botanicals. Thus, we call for sustainable investment into this challenging but increasingly important research field to encourage innovation, to nurture good practice and bring about breakthroughs.
Original languageEnglish
Pages (from-to)S19-S20
Number of pages2
JournalScience
Volume346
Issue number6216
Early online date19 Dec 2014
DOIs
Publication statusPublished - 19 Dec 2014

Fingerprint

Dive into the research topics of 'The hunt for antifibrotic and profibrotic botanicals'. Together they form a unique fingerprint.

Cite this